Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | FERMT2 | Q96AC1 | 4/20 | 0.75 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.72 |
| ▸ | CDK1 | P06493 | 1/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11757988 | 0.96 | CCR1 (0.86) | CCR1CYP1A2FERMT2NR4A2CDK1 | |
| SCHEMBL23883151 | 0.94 | CCR1 (0.84) | CCR1CYP1A2FERMT2NR4A2CDK1 | |
| SCHEMBL11758461 | 0.94 | CCR1 (0.84) | CCR1CYP1A2FERMT2NR4A2CDK1 | |
| SCHEMBL11756506 | 0.94 | CCR1 (0.84) | CCR1CYP1A2FERMT2NR4A2CDK1 | |
| Hydrochloric Acid SCHEMBL11758124 | 0.93 | CCR1 (0.82) | CCR1CYP1A2FERMT2NR4A2CDK1 | |
| SCHEMBL1855080 | 0.91 | CYP1A2 (0.82) | CCR1CYP1A2FERMT2NR4A2CDK1 | |
| SCHEMBL12643220 | 0.90 | CCR1 (0.97) | CCR1CYP1A2FERMT2NR4A2HRH3 | |
| SCHEMBL15481296 | 0.90 | CCR1 (0.97) | CCR1CYP1A2FERMT2NR4A2HRH3 | |
| SCHEMBL17527057 | 0.90 | CCR1 (0.97) | CCR1CYP1A2FERMT2NR4A2HRH3 | |
| SCHEMBL10179919 | 0.89 | CCR1 (0.75) | CCR1CYP1A2FERMT2NR4A2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493420-B2 | Quinoline derivatives and uses thereof | PORTLAND STATE UNIVERSITY (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493420-B2 | Quinoline derivatives and uses thereof | PORTLAND STATE UNIVERSITY (US) | 2016-11-15 | — | — | US | disclosed |
| US-8658648-B2 | Modified chloroquines with single ring moiety or fused ring moiety | DESIGNMEDIX, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658648-B2 | Modified chloroquines with single ring moiety or fused ring moiety | DESIGNMEDIX, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130310348-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | STATE UNIVERSITY (US) | 2013-11-21 | — | — | US | disclosed |
| US-8524739-B2 | Quinoline derivatives and uses thereof | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524739-B2 | Quinoline derivatives and uses thereof | STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110257160-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | Board of Higher Education on behalf of Portland State University | 2011-10-20 | — | — | US | disclosed |
| US-20110257160-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | Board of Higher Education on behalf of Portland State University | 2011-10-20 | — | — | US | disclosed |
| US-20110251210-A1 | MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY | PORTLAND STATE UNIVERSITY (US) | 2011-10-13 | — | — | US | disclosed |
| US-7947701-B2 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | SANOFI-AVENTIS (FR) | 2011-05-24 | — | — | US | disclosed |
| WO-2010086351-A1 | 3'-N-SUBSTITUTED 9-DEOXO-9A-METHYL-9A-AZA-HOMOERYTHROMYCIN HAVING ANTIMALARIAL ACTIVITY | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086351-A1 | 3'-N-SUBSTITUTED 9-DEOXO-9A-METHYL-9A-AZA-HOMOERYTHROMYCIN HAVING ANTIMALARIAL ACTIVITY | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2010-08-05 | — | — | WO | disclosed |
| EP-1687312-B1 | DUAL MOLECULES CONTAINING PEROXY DERIVATIVE, THE SYNTHESIS AND THERAPEUTIC APPLICATIONS THEREOF | CENTRE NAT RECH SCIENT (FR) | 2010-07-14 | — | — | EP | disclosed |
| WO-2010065925-A1 | MODIFIED CHLOROQUINES WITH BRANCHED MOIETY | DESIGNMEDIX, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2009016142-A1 | 9-DEOXO-9A-METHYL-9A-AZA-9A-HOMOERYTHROMYCIN A DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MALARIA | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2009-02-05 | — | — | WO | disclosed |
| US-20080188462-A1 | Quinoline Derivatives And Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-08-07 | — | — | US | disclosed |
| US-20080188462-A1 | Quinoline Derivatives And Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-08-07 | — | — | US | disclosed |
| US-20070021423-A1 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021423-A1 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251210-A1 | MODIFIED CHLOROQUINES WITH SINGLE RING MOIETY OR FUSED RING MOIETY | QARS1, MAVS, QDPR | CCR1 2418/4885CYP1A2 1668/4885FERMT2 4539/4885 |
| US-20130310348-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | RECQL, QARS1, QTRT1 | CCR1 3594/4885CYP1A2 446/4885FERMT2 3817/4885 |
| US-20110257160-A1 | QUINOLINE DERIVATIVES AND USES THEREOF | RECQL, QARS1, QTRT1 | CCR1 3594/4885CYP1A2 446/4885FERMT2 3817/4885 |
| US-20080188462-A1 | Quinoline Derivatives And Uses Thereof | RECQL, QARS1, QTRT1 | CCR1 3594/4885CYP1A2 446/4885FERMT2 3817/4885 |
| US-20070021423-A1 | Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof | PRDX2, PRDX1, PRDX5 | CCR1 4443/4885CYP1A2 210/4885FERMT2 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.